Biotech Event Tracker

274 events

Date	Symbol	Description	Type	Disease	Designation	Success Rating
Q4 2016	XENE	Xenon Pharmaceuticals (XENE) Phase 2 Results of XEN801 for Acne	Phase 2 Results	Other	None
Q4 2016	INNL	Innocoll Holdings (INNL) NDA Filing of XARACOLL for Post-Operative Pain	NDA Submission	Other	None
Q1 2017	VRTX	Vertex (VRTX) Phase 3 Results of VX-661for Cystic Fibrosis	Phase 3 Results	Other	Breakthrough Therapy, Orphan Drug
Q4 2016	PGNX	Proteon Therapeutics (PRTO) Phase 3 Results of Vonapanitase for Arteriovenous Fistula	Phase 3 Results	Cardiovascular	Fast Track, Orphan Drug
11/17/2016	APRI	Apricus Biosciences (APRI) NDA Filing of Vitaros for Erectile Dysfunction	NDA Submission	Other	None
Not General	TBPH	Theravance Biopharma (TBPH) Phase 2b Results of Velusetrag for Gastroparesis	Phase 2b Results	Other	None
H1 2017	VBLT	VBL Therapeutics (VBLT) Phase 3 Interim Results of VB-111 for Solid Tumors	Phase 3 Results	Oncology	Fast Track, Orphan Drug
Q4 2017	VBLT	VBL Therapeutics (VBLT) Phase 3 Full Results of VB-111 for Solid Tumors	Phase 3 Results	Oncology	Fast Track, Orphan Drug
Q4 2016	AMRN	Amarin Corporation (AMRN) Phase 3 Results of Vascepa for Patients with Elevated Triglyceride Level	Phase 3 Results	Other	None
H2 2016	BOTA	Biota Pharmaceuticals (BOTA) Phase 2b Results of Vapendavir for Human Rhinovirus Infection	Phase 2b Results	Infectious Disease	None